HAP, or hospital-acquired pneumonia is acquired by patients after he or she is being admitted in the hospital for more than 48 hours. The public healthcare system is facing a tough challenge in the form of HAP as it is the second most hospital acquired infection. Pneumonia causes agitation of lungs and mainly affects the alveoli which are a microscopic air sac. Primary causes of HAP are bacteria or viral infections and it can be differentiated based on how the infection was acquired by the patient.
Pneumonia is a leading cause of death across the globe with fatality rate of 4-10%. Hospital-acquired pneumonia is the most common form among the others and it has a huge impact on life style of patient population. Further, it is associated with a high mortality rate and requires immediate medical intervention. Because of this, there is a huge demand of pharmacological intervention ineffective management of the disease. According to Infectious Control and Epidemiology, the overall incidence in the US is 1.6% and represents 3.63 per 1000 patients. Increasing prevalence among the healthcare settings led to a potential growth of the market.
Further, increasing risk factors with longer hospital stays led to the development of the development of standard guidelines for effective management with pharmacological interventions. All this factors led to potential growth of the market. Developing economies like North America and Europe account major share in global market. North America is a major shareholder and it is dominated by the US due to well-established healthcare systems. Europe is the second major shareholder in the global market and is dominated by the UK, Germany, France, and Italy. Asia Pacific is the most opportunistic space for manufacturers due to high prevalence. Further, changing healthcare policies in the Asia Pacific led to the robust growth of the market. Latin America and Rest of World represented as fast-growing regions in the global market due to the increasing incidence and changing healthcare policies.